MorphoSys Announces Clinical Milestone in Blood Disorders Program

MorphoSys AG / MorphoSys Announces Clinical Milestone in Blood Disorders Program . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that it has received a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of blood disorders. This becomes the eleventh therapeutic antibody made using MorphoSys's technologies that Novartis is evaluating in clinical trials. The associated milestone payment was booked in Q2 2015.

"With eleven therapeutic antibody programs in clinical development to date, our alliance with Novartis has resulted in a substantial drug candidate portfolio," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news represents the second clinical milestone with our partners during the course of this year."

MorphoSys's collaboration with Novartis has resulted in eleven clinical programs to date, six of which are in Phase 1 development, with another four programs in Phase 2 and one in Phase 3. In total, MorphoSys's proprietary and partnered clinical pipeline currently comprises 24 unique antibody molecules, which are being evaluated in more than 50 clinical trials.

 

 

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.